Assembly Biosciences (NASDAQ:ASMB) Earns “Buy” Rating from HC Wainwright

Assembly Biosciences (NASDAQ:ASMB)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a report issued on Tuesday, Marketbeat Ratings reports. They presently have a $50.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target indicates a potential upside of 66.61% from the stock’s current price.

A number of other equities analysts have also commented on ASMB. Guggenheim reaffirmed a “buy” rating and issued a $43.00 price objective on shares of Assembly Biosciences in a research note on Thursday, May 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Assembly Biosciences in a report on Friday, July 17th. Wall Street Zen downgraded Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, Mizuho set a $45.00 target price on Assembly Biosciences and gave the company an “outperform” rating in a report on Monday, June 15th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Assembly Biosciences presently has a consensus rating of “Moderate Buy” and an average target price of $44.00.

Assembly Biosciences Stock Down 8.9%

ASMB opened at $30.01 on Tuesday. The firm has a market cap of $476.86 million, a PE ratio of 29.42 and a beta of 1.10. The business has a fifty day simple moving average of $26.24 and a 200-day simple moving average of $27.40. Assembly Biosciences has a fifty-two week low of $20.23 and a fifty-two week high of $39.71.

Assembly Biosciences (NASDAQ:ASMB) last announced its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.52. The company had revenue of $13.37 million for the quarter, compared to analyst estimates of $8.60 million. Assembly Biosciences had a negative return on equity of 0.02% and a negative net margin of 0.06%. On average, equities research analysts anticipate that Assembly Biosciences will post 1.9 EPS for the current fiscal year.

Institutional Investors Weigh In On Assembly Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in ASMB. RA Capital Management L.P. bought a new position in shares of Assembly Biosciences in the third quarter valued at approximately $26,122,000. Paradigm Biocapital Advisors LP bought a new stake in shares of Assembly Biosciences during the 4th quarter worth $22,625,000. Parkman Healthcare Partners LLC bought a new stake in shares of Assembly Biosciences during the 3rd quarter worth $6,425,000. Vanguard Group Inc. grew its stake in Assembly Biosciences by 97.8% in the 3rd quarter. Vanguard Group Inc. now owns 502,112 shares of the biopharmaceutical company’s stock valued at $12,854,000 after buying an additional 248,287 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. acquired a new position in Assembly Biosciences in the 4th quarter valued at $5,476,000. 19.92% of the stock is currently owned by institutional investors and hedge funds.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.